Abiopharma

Adaptimmune Announces Changes to Board and Executive Leadership Team

BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use Disorder

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement

BioLife Solutions to Participate in Upcoming Investor Conferences in November and December 2025

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London

GE HealthCare announces Flyrcado milestone: Strong pilot results drive broader rollout at CVAUSA

Castle Biosciences - Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

Halozyme - Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab